ReviewFrontiers in oncology2026
Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is a highly malignant tumor of the digestive system, characterized by the lack of effective methods for early screening, diagnosis and treatment. Despite its low incidence rate, it has an extremely high mortality rate. In recent years, the number of confirmed cases worldwide has been on a continuous rise, making PC the sixth leading cause of cancer-related deaths across the globe. At present, clinical treatment strategies including surgical resection, chemotherapy, radiotherapy, molecular targeted therapy and biological immunotherapy have not significantly improved the survival prognosis of PC patients. Therefore, exploring safe and effective therapeutic approaches and clarifying the etiological mechanisms of PC have become key priorities in clinical treatment. Its occurrence and progression involve multilayered mechanisms, including environmental exposure, genetic susceptibility, metabolic abnormalities, chronic inflammation, progression of precancerous lesions, remodeling of the tumor microenvironment, and immune escape. Based on a summary of smoking, alcohol consumption, obesity, diabetes, chronic pancreatitis, genetic mutations, and multiple signaling pathways, this article further provides a critical review from the perspectives of evidence strength, mechanistic plausibility, and clinical translational value. It aims to deepen the understanding of the initiation and progression of pancreatic cancer and to provide new directions for its early diagnosis and precision treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.